Nooglutyl – (112193-35-8)

Nooglutyl is a nootropic agent developed at the Research Institute of Pharmacology within the Russian Academy of Medical Sciences, primarily investigated for its potential in treating amnesia. Structurally, it shares similarities with picamilon, being N-5-HydroxyNicotinoyl-L-Glutamic acid.

Nooglutyl exhibits a range of central nervous system effects in animal models, suggesting its potential as a therapeutic agent. It has been studied for its antimotion effects, its impact on benzodiazepine withdrawal syndrome, and its role in mitigating symptoms of intracerebral posttraumatic hematoma.

Additionally, research indicates that Nooglutyl may influence the ischemic lesion zone and memory in rats following middle cerebral artery occlusion. Despite its promising applications, Nooglutyl remains a subject of ongoing research, with its full therapeutic potential yet to be fully realized.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Nooglutyl
https://www.medkoo.com/products/22419
https://link.springer.com/article/10.1007/BF02543440
https://drugs.ncats.io/drug/AHS2YHS2MG